Skip to content
naulon
Not checkedNot checked for notices yet.

Effectiveness of oral antibiotics for treating pyelonephritis caused by extended‐spectrum beta‐lactamase‐producing Enterobacteriaceae: A case series

Norihiko Terada, Naoya Itoh, Hanako Kurai

Journal of General and Family Medicine · 2020

doi:10.1002/jgf2.320 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background Recently, the spread of multidrug‐resistant bacteria has become a global problem. Extended‐spectrum beta‐lactamase (ESBL)‐producing Enterobacteriaceae (enterobacteria) is one example. The incidence of urinary tract infections caused by ESBL‐producing enterobacteria has been increasing in some Japanese community settings. Currently, there is insufficient evidence on the effectiveness of oral antibiotics used for the treatment of pyelonephritis caused by ESBL‐producing enterobacteria. We investigated the effectiveness of oral antibacterial agents against pyelonephritis caused by ESBL‐producing Enterobacteriaceae . Methods The records of patients who had been treated for pyelonephritis caused by ESBL‐producing enterobacteria with oral antibiotics between April 1, 2014, and March 31, 2019, were reviewed retrospectively to assess the effectiveness of oral antibiotic treatment. Results A total of seven cases were identified, including 1 patient with a positive blood culture and one patient with a Pitt bacteremia score of four points, indicating that the infections were severe. The antibiotics used to treat pyelonephritis were amoxicillin‐clavulanic acid (n = 3), minocycline (n = 1), levofloxacin (n = 3), and sulfamethoxazole‐trimethoprim with amoxicillin‐clavulanic acid (n = 1). None of the patients had recurrence of pyelonephritis in the 60 days following oral antibiotic treatment, and there were no deaths during the 60‐day follow‐up period. Conclusions These antibiotics should be considered for oral treatment of pyelonephritis caused by ESBL‐producing enterobacteria. However, as there is insufficient evidence available on the effectiveness of these antibiotics for the management of ESBL‐producing enterobacterial infections, further large‐scale prospective studies are needed.

Abstract licence: CC BY-NC

References23

  1. 3.

22 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.